Ikarian Capital, LLC 89bio, Inc. Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $1.4 Million - $3.23 Million	254,000 Added 127.0%	454,000 $5.78 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $604,000 - $1.4 Million	200,000 New	200,000 $1.16 Million
Q1 2021 May 17, 2021	SELL	$20.22 - $26.73 $663,195 - $876,717	-32,799 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$23.16 - $28.08 $7.12 Million - $8.63 Million	-307,437 Reduced 90.36%	32,799 $799,000
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $8.28 Million - $13.2 Million	340,236 New	340,236 $8.73 Million

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.